Vandetanib in children and adolescents with multiple endocrine neoplasia type 2b associated medullary thyroid carcinoma

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4239-4248

  Fox, Elizabeth ^a,b   Widemann, Brigitte C ^b   Chuk, Meredith K ^b   Marcus, Leigh ^b   Aikin, Alberta ^b   Whitcomb, Patricia O ^b   Merino, Maria J ^b   Lodish, Maya ^c   Dombi, Eva ^b   Steinberg, Seth M ^b   Wells, Samuel A ^b   Balis, Frank M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CLINDAMYCIN; CORTICOTROPIN; DAPSONE; ENALAPRIL; FLUOCINOLONE ACETONIDE; HYDROCORTISONE; LEVOTHYROXINE; LOPERAMIDE; MINOCYCLINE; PROTEIN RET; TETRACYCLINE; VANDETANIB; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RET PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRADYCARDIA; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CODON; CONSTIPATION; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FLUSHING; GENE MUTATION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROFIBROMATOSIS; NEUTROPENIA; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; PROTO ONCOGENE; QT PROLONGATION; RECOMMENDED DRUG DOSE; RET GENE; SCHOOL CHILD; SIDE EFFECT; TELANGIECTASIA; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TUMOR VOLUME; VOMITING; ADVERSE DRUG REACTION; CARCINOMA, MEDULLARY; CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETICS; GERMLINE MUTATION; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; THYROID NEOPLASMS;

ADOLESCENT; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84881256059     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0071     Document Type: Article

References (35)

1. Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol 2011;7:596-607.
2. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
3. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579-83.
4. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
5. Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 2006;66:10741-9.
6. Wells SA Jr., Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-47; discussion 47-50.
7. Wells SA Jr., Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998;106:29-34.
8. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-13.
9. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
10. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48.
11. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48:265-73.
12. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
13. vanVeelen W, deGroot JWB, Acton DS, Hofstra RMW, Hoppener WM, Links TP, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. J Internal Med 2009;266:126-40.
14. Iacobone M, Niccoli-Sire P, Sebag F, DeMicco C, Henry J-F. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operative patients with elevated serum calcitonin. World J Surg 2002;26:886-90.
15. Mirallie E, Iacobone M, Sebag F, Henry JF. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol 2004;30:790-5.
16. Ebert EC. The thyroid and the gut. J Clin Gastroenterol 2010;44:402-6.
17. Fabian E, Kump P, Krejs GJ. Diarrhea caused by circulating agents. Gastroenterol Clin North Am 2012;41:603-10.
18. Liu H, Singla A, Ao M, Gill RK, Venkatasubramanian J, Rao MC, et al. Calcitonin receptor-mediated CFTR activation in human intestinal epithelial cells. J Cell Mol Med 2011;15:2697-705.
19. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-90.
20. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
21. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 2005;65:3538-41.
22. Wells SA Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41.
23. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
24. Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010;28:4762-8.
25. Kim A, Dombi E, Solomon J, Fox E, Balis FM, Widemann BC. Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials. Clin Cancer Res 2011;17:5982-90.
26. Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010;28:5174-81.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
28. Wells SA Jr., Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
29. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71.
30. Wells S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 2007;25 (June 20 Suppl):Abstr 6018.
31. Lantieri F, Caroli F, Ceccherini I, Griseri P. The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a metaanalysis study. Int J Cancer 2012; doi 10.1002/ijc.27967 [Epub ahead of print].
32. Machens A, Frank-Raue K, Lorenz K, Rondot S, Raue F, Dralle H. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin Endocrinol 2012;76: 691-7.
33. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007;67: 6956-64.
34. Brassard M, Neraud B, Trabado S, Salenave S, Brailly-Tabard S, Borget I, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 2011;96:2741-9.
35. Schoffski P, Elisei R, Muller S, Brose MS, Shan M, Licitra LF, et al. An international, double-blind, randomized, placebo-controlled, phase 3 trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. J Clin Oncol 2012;30S:Abstract nr 508.